NCT03557502

Brief Summary

This is a clinical trial to determine whether 30 sessions of heat therapy in the form of hot water immersion is better than 30 sessions of traditional aerobic exercise training on blood pressure reduction in people with elevated or Stage 1 hypertension.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable hypertension

Timeline
Completed

Started Dec 2019

Longer than P75 for not_applicable hypertension

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 4, 2018

Completed
11 days until next milestone

First Posted

Study publicly available on registry

June 15, 2018

Completed
1.5 years until next milestone

Study Start

First participant enrolled

December 1, 2019

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2023

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

June 4, 2025

Completed
Last Updated

June 4, 2025

Status Verified

September 1, 2022

Enrollment Period

4.1 years

First QC Date

June 4, 2018

Results QC Date

March 20, 2025

Last Update Submit

May 14, 2025

Conditions

Keywords

Stage 1 hypertensionArterial Stiffness

Outcome Measures

Primary Outcomes (1)

  • Blood Pressure Reduction: Change in Systolic and Diastolic Ambulatory Blood Pressure (mmHg) After 30 Sessions of Intervention

    Ambulatory blood pressure (ABP) was measured at baseline (PRE) and after 30 heat therapy or exercise training sessions (POST) over the course of 8-10 weeks. Two individuals performed post-intervention testing after completing only 27 sessions (1 in each group). Participants arrived at the lab and were fitted with an oscillometric blood pressure cuff attached to an ambulatory blood pressure monitor. The monitor was programmed to inflate and assess blood pressure every 20 min during self-reported waking hours and every 60 min during self-reported sleeping hours. Waking and sleeping times and measurement frequency were replicated at POST within each participant. Ambulatory blood pressure data were analyzed as 24-h total for both systolic and diastolic blood pressure. Change was calculated as the value at the POST timepoint minus the value at the PRE timepoint.

    10 weeks

Secondary Outcomes (1)

  • Arterial Stiffness: Change in Carotid-femoral Pulse Wave Velocity (m/s) From Pre (Baseline) to Post (After 30 Sessions of Intervention)

    10 weeks

Study Arms (2)

Heat Therapy Group

EXPERIMENTAL

Group will undergo 30 sessions of heat therapy over approximately 10 weeks. Sessions will require subjects to be immersed in hot water for up to 45 minutes per session.

Other: Heat Therapy Group

Aerobic Exercise Group

EXPERIMENTAL

Group will undergo 30 sessions of aerobic exercise training over approximately 10 weeks. Sessions will require subjects to exercise on a cycle ergometer for up to 45 minutes per session.

Other: Aerobic Exercise Group

Interventions

30 sessions of immersion in 40.5 degree celsius water for 45 minutes per session

Heat Therapy Group

30 sessions of aerobic exercise training for 45 minutes at 60% of VO2peak

Aerobic Exercise Group

Eligibility Criteria

Age35 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Systolic Blood Pressure 120 mmHg or greater and less than 180 mmHg or Diastolic Blood Pressure of 80mmHg or greater and less than 120mmHg

You may not qualify if:

  • Secondary hypertension; diagnosed cardiovascular disease other than hypertension; taking anti-hypertensive drugs; BMI of 35 or greater; fasting glucose greater than 125 mg/dl; women who are pregnant, nursing, or desiring to become pregnant.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Oregon

Eugene, Oregon, 97403, United States

Location

MeSH Terms

Conditions

HypertensionCardiovascular Diseases

Condition Hierarchy (Ancestors)

Vascular Diseases

Results Point of Contact

Title
Dr. Christopher Minson
Organization
University of Oregon

Study Officials

  • Christopher T Minson, PhD

    University of Oregon

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Randomized parallel study design
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 4, 2018

First Posted

June 15, 2018

Study Start

December 1, 2019

Primary Completion

December 30, 2023

Study Completion

December 30, 2023

Last Updated

June 4, 2025

Results First Posted

June 4, 2025

Record last verified: 2022-09

Data Sharing

IPD Sharing
Will share

De-identified data will be placed in Research Electronic Data Capture (REDCap)

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR
Time Frame
1 year following completion of subject testing
Access Criteria
Access to REDCap
More information

Locations